Comparative safety of sulfonylureas in type 2 diabetes: Clinical sequelae of KATP blockade

  • September 27, 2019 from 12:00-1:00 pm
  • Christiana Hospital, Room 1100
  • No remote connections or recording as requested by speaker

Speaker: Charles E. Leonard, PharmD, MSCE, University of Pennsylvania

Sulfonylureas remain important in the armamentarium of clinicians treating type 2 diabetes mellitus. Agents within this drug class are at least initially effective, generally well tolerated, and inexpensive. Yet, there are major concerns for serious hypoglycemia and untoward cardiovascular effects. To help inform second-line antidiabetic therapy prescribing decisions, it is critical to understand the safety of individual sulfonylureas. This talk will examine Dr. Leonard’s population-based pharmacoepidemiologic studies elucidating adverse effects of sulfonylureas, including investigations of: a) serious hypoglycemia potentiated by drug interactions; and b) sudden cardiac arrest.

Stay Connected

Join the ACCEL newsletter and keep up to date with the latest news, events and funding opportunities!

[yikes-mailchimp form="1"]